EC Number   |
Inhibitors |
Structure |
|---|
   3.4.24.16 | (2R)-2-[(4-biphenylylsulfonyl)amino]-3-phenylpropionic acid |
- |
   |
| 3.4.24.16 | (2R)-[(4-biphenylylsulfonyl)amino]-N-hydroxy-3-phenylpropionamide |
- |
|
| 3.4.24.16 | 1,10-phenanthroline |
- |
|
| 3.4.24.16 | 1,10-phenanthroline |
1 mM, 95% inhibition |
|
| 3.4.24.16 | 1-adamantan-2-yl-3-[2-[2,3-bis-(2-chloro-phenyl)-pyrazolidin-1-yl]-2-oxo-ethyl]-urea |
racemic |
|
| 3.4.24.16 | 3-(4-phenoxyphenylsulfonyl)-propylthiirane |
- |
|
| 3.4.24.16 | 3-[(2S)-1-[(3R)-3-(2-chlorophenyl)-2-(2-fluorophenyl)pyrazolidin-1-yl]-1-oxopropan-2-yl]-1-(adamantan-2-yl)urea |
R-stereomer, allosteric inhibition of neurolysin, mixed-type inhibition kinetics, the bound inhibitor disrupts activity by preventing a hinge-like motion associated with substrate binding and catalysis. The inhibitor reverses a substrate-associated conformational change |
|
| 3.4.24.16 | acetyl-neurotensin(8-13) |
degradation of tritiated neurotensin |
|
| 3.4.24.16 | acetyl-neurotensin(8-13) |
inhibits degradation of 3-carboxy-7-methoxycoumaryl-Pro-Leu-Gly-Pro-D-Lys-dinitrophenyl |
|
| 3.4.24.16 | acetyl-neurotensin(8-13)aminde |
degradation of tritiated neurotensin |
|
